Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: kinase inhibitor drug conjugates - Tarveda Therapeutics

Next Previous
Search
Drug Profile

Research programme: kinase inhibitor drug conjugates - Tarveda Therapeutics

Latest Information Update: 21 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Madrigal Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 21 Aug 2023 Preclinical development is ongoing in USA (SciClone Pharmaceuticals, Pipeline August 2023)
  • 28 Mar 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
  • 16 Sep 2021 Kinase inhibitor drug conjugates licensed to SciClone Pharmaceuticals in China, Macau, Hong Kong, Taiwan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top